Core sales growth of 20 percent will be led by biopharma, India formulations and CRAMS business, analysts say, adding Biopharma will be lead by immunosuppressants (Serolimus) and insulin in emerging markets.
first published: Jan 21, 2014 06:42 pm
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
